Clinical trial
A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
NCT05194163 is registered in ClinicalTrials.gov with Neurokine Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
- Lead sponsor
- Neurokine Therapeutics
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 1, 2022
- Completion date
- November 30, 2024
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.